NCT05564338 2023-06-07
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
BeiGene
Phase 3 Withdrawn
Clinical Trials
10 trialsNCT04465734 2022-05-05
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
Shanghai Henlius Biotech
Phase 3 Withdrawn
NCT04546802 2020-09-14
HATCHeT
Bayside Health
Phase 3 Withdrawn
NCT03744247 2019-05-02
Lenvatinib Plus PD-1 Antibody Versus Lenvtinib Alone for Advanced HCC
Sun Yat-sen University
Phase 3 Withdrawn
NCT03791918 2019-05-02
Lenvatinib Plus PD-1 Antibody vs TACE for Intermediate-stage HCC Beyond Up-to-seven Criteria
Sun Yat-sen University
Phase 3 Withdrawn
NCT02149771 2018-04-19
Combination Treatment for Advanced Liver Cancer
Shanghai Zhongshan Hospital
Phase 3 Withdrawn
NCT02004210 2016-04-27
A Phase 3 Trial Comparing TACE and TARE in Unilobar Advanced Hepatocellular Carcinoma
Seoul National University Hospital
Phase 3 Withdrawn
NCT01327521 2012-06-11
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
Stanford University
Phase 3 Withdrawn
NCT01318200 2012-02-20
Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular Carcinoma (HCC)
Accuray Incorporated
Phase 3 Withdrawn
NCT01245582 2011-11-09
SECOX
Sanofi
Phase 3 Withdrawn